Min Lu
Executive Director - Biology Eli Lilly & Co.
Min earned his MD degree in China and later pursued a PhD and postdoctoral research in the United States, focusing on vascular biology, insulin resistance, and obesity. He successfully completed all three steps of the United States Medical Licensing Examination before transitioning into the biopharmaceutical industry. Over the years, Min has held key roles at several pharmaceutical and biotech companies, leading initiatives in target identification and validation, pharmacology, biomarker discovery, and early-stage development, primarily in the areas of metabolic disorders and fibrosis. Currently at Eli Lilly, Min heads a discovery team dedicated to advancing lead molecules aimed at targeting tissue remodeling and organ failure.
Seminars
- Assessing past and present targets, what has the field learned from antifibrotic failures, and is there still potential in pathways like TGF-β?
- Exploring emerging therapeutic strategies from repair and regeneration to RNA-based therapies, cell and gene therapy, and immunomodulation
- Identifying unmet opportunities by exploring what mechanisms remain underexplored, where should research efforts be focused next to drive meaningful progress?
Understanding the complex interplay between immune responses, epithelial dysfunction, and regeneration failures is crucial for advancing early intervention strategies in IPF. This workshop will explore the molecular underpinnings of immune cell activity, inflammation, and epithelial repair in disease progression. Through expert insights, we will dissect how disrupted biological processes drive fibrosis and discuss emerging therapeutic approaches targeting immune and epithelial pathways.
Get ready to explore:
Epithelial Dysfunction & Regeneration Failure in IPF
- The molecular biology of epithelial injury and its role in disease progression
- Why failed regeneration is central to fibrosis development
- Emerging biomarkers linking epithelial signatures to disease severity
The Enigmatic Role of Inflammation in IPF
- Understanding the paradox: why anti-inflammatory therapies worsen outcomes
- The potential of immune-targeting therapies and companies exploring this space
Bridging Immunology & Fibrosis in IPF Treatment
- Key immune players: which inflammatory cells are present, and what role do they play?
- How immune modulation could be leveraged for therapeutic intervention
- The next steps in developing immune-based therapies for IPF
